TOI - The Oncology Institute, Inc. Latest News | Finranks

TOI - The Oncology Institute, Inc. Latest News | Finranks

The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript

The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript

The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026

CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025.

Topicus: Recurring VMS Revenues And M&A Discipline Remain Bullish

Topicus: Recurring VMS Revenues And M&A Discipline Remain Bullish

Topicus is part of a Constellation Software spin-out. However, they still roll up European VMS firms across public and private niches. These subsidiaries remain autonomous business units, and TOITF's M&A portfolio blends TSS (over 180 companies) with the Topicus platform cluster. This is how TOITF can serve SaaS targeting education, healthcare, government, finance, legal, and other regulated verticals.

U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care

U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care

DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the “Company”), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (NASDAQ: TOI).

The Oncology Institute Announces Leadership Promotions

The Oncology Institute Announces Leadership Promotions

Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer.

The Oncology Institute: Making Progress

The Oncology Institute: Making Progress

The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point.

The Oncology Institute Announces Resignation of Board Member Gabe Ling

The Oncology Institute Announces Resignation of Board Member Gabe Ling

CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise.

Videos

No Data

There is no data to display